Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service

References

• Dukes M NG. The importance of adverse reactions in drug regulation. Drug Safety 1990; 5: 3–6
   Google Scholar
• Coulter D M, Bate A, Meyboom R HB, Lindquist M, Edwards I R. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study. BMJ 2001; 322: 1207–1209
   Google Scholar
• Hagg S, Spigset O, Bate A, Soderstrom T G. Myocarditis related to clozapine treatment. Journal of Clinical Psychopharmacology 2001; 21: 382–388
   Google Scholar
• Grenade L L, Graham D, Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. New England Journal of Medicine 2001; 345: 224
   Google Scholar
• Committee on Safety in Medicines Myocarditis with antipsychotics: recent cases with clozapine. Current Problems in Pharmacovigilance 1993; 19: 9–10
   Google Scholar
• Kilian J G, Kerr K, Lawrence C, Celermajer D S. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841–1845
   Google Scholar
• Catalano G, Catalano M C, Wetter R LF. Clozapine induced polyserositis. Clinical Neuropharmacology 1997; 20: 352–356
   Google Scholar
• Daly J M, Goldberg R J, Braman S S. Polyserositis associated with clozapine treatment. American Journal of Psychiatry 1992; 149: 1274–1275
   Google Scholar
• Kay S E, Doery J, Sholl D. Clozapine associated pericarditis and elevated yroponin I. Australian and New Zealand Journal of Psychiatry 2002; 36: 143–144
   Google Scholar
• Murko A, Clarke S, Black D W. Clozapine and pericarditis with pericardial effusion. American Journal of Psychiatry 2002; 159: 494
   Google Scholar
• Phan K LD, Taylor S F. Clozapine-associated cardiomyopathy. Psychosomatics 2002; 43: 248
   Google Scholar
• Povlsen U J, Noring U, Fog R, Gerlach J. Tolerability and therapeutic effect of clozapine. Acta Psychiatrica Scandinavica 1985; 71: 176–185
   Google Scholar
• Ketch J, Herd A, Ludwig L. ST segment elevations without myocardial infarction in a patient on clozapine. American Journal of Emergency Medicine 1996; 14: 111–112
   Google Scholar
• Tie H, Walker B D, Singleton C B, Burstill J A, Wyse K R. Clozapine and sudden death. Journal of Clinical Psychopharmacology 2001; 21: 630–631
   Google Scholar
• Varma S, Achan K. Dysrhythmia associated with clozapine. Australian and New Zealand Journal of Psychiatry 1999; 33: 118–119
   Google Scholar
• Low R A, Fuller M A, Popli A. Clozapine induced atrial fibrillation. Journal of Clinical Psychopharmacology 1998; 18: 170–171
   Google Scholar
• Koren W, Kreis Y, Duchowiczny K, et al. Lactic acidosis and fatal myocardial failure due to clozapine. Annals of Pharmacotherapy 1997; 31: 168–170
   Google Scholar
• Reznik I, Volchek L, Mester R, et al. Myotoxicity and neurotoxicity during clozapine treatment. Clinical Neuropharmacology 2000; 23: 276–280
   Google Scholar
• Agelink M W, Majewski T, Wurthmann C, et al. Effects of newer atypical antipsychotics on autonomic neurocardiac function. A comparison between amisulpride, olanzapine, sertindole, and clozapine. Journal of Clinical Psychopharmacology 2001; 21: 8–13
   Google Scholar
• Cohen H, Loewnthal U, Matar M, Kotler M. Association of autonomic dysfunction and clozapine. British Journal of Psychiatry 2001; 179: 167–171
   Google Scholar
• Koren W, Koren E, Nacasch N, Ehrenfeld M, Gur H. Rhabdomyolysis associated with clozapine treatment in a patient with decreased calcium-dependent potassium permeability of cell membranes. Clinical Neuropharmacology 1998; 21: 262–264
   Google Scholar
• Meltzer H Y, Cola P A, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology 1996; 15: 395–405
   Google Scholar
• Maes M, Bosmans E, Kenis G, de Jong R, Smith R S, Meltzer H Y. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophrenia Research 1997; 26: 221–225
   Google Scholar
• Song C, Lin A, Kenis G, Bosmans E, Maes M. Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist. Schizophrenia Research 2000; 42: 157–164
   Google Scholar
• Hinze-Selch D, Becker E W, Stein G M, et al. Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology 1998; 19: 114–122
   Google Scholar
• Bandelow B, Degner D, Kreusch U, Ruther E. Myocarditis under therapy with clozapine. Schizophrenia Research 1995; 17: 293–294
   Google Scholar
• Kirpekar V C, Deshpande S M, Joshi P P. Reversible myocarditis in a patient receiving clozapine. Indian Heart Journal 2001; 53: 779–781
   Google Scholar
• Novartis Pharmaceuticals Canada. Association of clozaril (clozapine) with cardiovascular toxicity [Dear Healthcare Professional letter]. Novartis Pharmaceuticals Canada, Dorval, QC 2003, Available at: http://www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/advisory/industry/clozaril_e.html (accessed 23 February 2003)
   Google Scholar
• Leo R J, Kreeger J L, Kim K Y. Cardiomyopathy associated with clozapine. Annals of Pharmacotherapy 1996; 30: 603–605
   Google Scholar
• Hoehns J D, Fouts M M, Kelly M W, Tu K B. Sudden cardiac death with clozapine and sertraline combination. Annals of Pharmacotherapy 2001; 35: 862–866
   Google Scholar
• Wooltorton E. Antipsychotic clozapine (Clozaril); myocarditis and cardiovascular toxicity. Canadian Medical Association Journal 2002; 166: 1185–1186
   Google Scholar
• Burke A P, Saenger J, Mullick F, Virmani R. Hypersensitivity myocarditis. Archives of Pathological and Laboratory Medicine 1991; 115: 764–769
   Google Scholar
• Fenoglio J J, McAllister H A, Mullick F G. Drug related myocarditis – hypersensitivity myocarditis. Human Pathology 1981; 12: 900–907
   Google Scholar
• Reid P, McArthur M, Pridmore S. Clozapine rechallenge after myocarditis. Australian and New Zealand Journal of Psychiatry 2001; 35: 249
   Google Scholar
• Cooper L T. Myocarditis. 2nd edn., J G Murphy. Lippincott, Williams & Wilkins, Philadelphia 2000
   Google Scholar
• Hahn E A, Hartz V L, Moon T E, et al. The Myocarditis Treatment Trial: design, methods and patient enrolment. European Heart Journal 1995; 16: 162–167
   Google Scholar
• Mason J W, O'Connell J B, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. New England Journal of Medicine 1995; 333: 269–275
   Google Scholar
• Caforio A LP, McKenna W J. Recognition and optimum management of myocarditis. Drugs 1996; 52: 515–525
   Google Scholar
• Lapierre Y D, Ghadirian A, St.Laurent J, Chaudhry R P. Clozapine in acute schizophrenia – efficacy and toxicity. Current Therapeutic Research 1980; 27: 391–400
   Google Scholar